Core Oncology announced it has closed on its acquisition of Mills Biopharmaceuticals, LLC, the brachytherapy division of Coloplast A/S. Founded in 1992, Mills Biopharmaceuticals, LLC of Oklahoma City, Okla, is the third largest domestic supplier of Iodine 125 and Palladium Pd-103 seeds for low dose prostate brachytherapy treatment. ProstaSeed has been commercially available since April of 1999 and is both CE marked and manufactured at ISO 9001:2000 standards. In early 2003 the company was acquired by Mentor Corporation. In June 2006 Coloplast acquired Mills Biopharmaceuticals as part of the urology portfolio from Mentor.
Travis Gay, President and CEO of Core Oncology, stated, "We have a leadership position today in the growing prostate brachytherapy market and look forward to building sales around the world as we continue to expand this product line and focus on the growing radiation therapy market. Through this acquisition, we now have the most advanced brachytherapy manufacturing plant in the industry, the lowest cost of assets, and a loyal base of customers at the leading-edge of therapy in this arena."
|
